Runx2 mediates epigenetic silencing of the bone morphogenetic protein-3B (BMP-3B/GDF10) in lung cancer cells

Department of Anatomy and Cell Biology, Rush University Medical Center, Armour Academic Center, 600 S, Paulina St, Suite 507, Chicago, IL, 60612, USA.
Molecular Cancer (Impact Factor: 5.4). 04/2012; 11:27. DOI: 10.1186/1476-4598-11-27
Source: PubMed

ABSTRACT The Runt-related transcription factor Runx2 is essential for bone development but is also implicated in progression of several cancers of breast, prostate and bone, where it activates cancer-related genes and promotes invasive properties. The transforming growth factor β (TGF-β) family member bone morphogenetic protein-3B (BMP-3B/GDF10) is regarded as a tumor growth inhibitor and a gene silenced in lung cancers; however the regulatory mechanisms leading to its silencing have not been identified.
Here we show that Runx2 is highly expressed in lung cancer cells and downregulates BMP-3B. This inverse relationship between Runx2 and BMP-3B expression is further supported by increased expression of BMP-3B in mesenchymal cells from Runx2 deficient mice. The ectopic expression of Runx2, but not DNA binding mutant Runx2, in normal lung fibroblast cells and lung cancer cells resulted in suppression of BMP-3B levels. The chromatin immunoprecipitation studies identified that the mechanism of Runx2-mediated suppression of BMP-3B is due to the recruitment of Runx2 and histone H3K9-specific methyltransferase Suv39h1 to BMP-3B proximal promoter and a concomitant increase in histone methylation (H3K9) status. The knockdown of Runx2 in H1299 cells resulted in decreased histone H3K9 methylation on BMP-3B promoter and increased BMP-3B expression levels. Furthermore, co-immunoprecipitation studies showed a direct interaction of Runx2 and Suv39h1 proteins. Phenotypically, Runx2 overexpression in H1299 cells increased wound healing response to TGFβ treatment.
Our studies identified BMP-3B as a new Runx2 target gene and revealed a novel function of Runx2 in silencing of BMP-3B in lung cancers. Our results suggest that Runx2 is a potential therapeutic target to block tumor suppressor gene silencing in lung cancer cells.

Download full-text


Available from: Jitesh Pratap, Feb 05, 2014
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Aim. To investigate clinical significance of runt-related transcription factor (RUNX)-2 in epithelial ovarian cancer (EOC). Methods. RUNX2 protein expression and its subcellular localization were detected by immunohistochemistry in 116 patients with EOC. Results. RUNX2 protein was predominantly expressed in cell nucleus of EOC tissues. The expression level of RUNX2 in EOC tissues was significantly higher than that in normal ovarian tissues (P < 0.001). In addition, the nuclear labeling index (LI) of RUNX2 in tumor cells was significantly associated with the advanced clinical stage of EOC tissues (P = 0.001). Moreover, EOC patients with high RUNX2 LI had significantly shorter overall (P < 0.001) and progression-free (P = 0.002) survival than those with low RUNX2 LI. Especially, subgroup analysis revealed that EOC patients with high clinical stages (III~IV) in high RUNX2 expression group demonstrated a significantly worse clinical outcome than those in low RUNX2 expression group, but patients with low clinical stages (I~II) had no significantly different prognosis between high and low RUNX2 expression groups. Conclusions. Our data suggest for the first time that RUNX2 overexpression is associated with advanced tumor progression and poor clinical outcome of EOC patients. RUNX2 might be a novel prognostic marker of EOC.
    BioMed Research International 10/2012; 2012:456534. DOI:10.1155/2012/456534 · 2.71 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: EBNA1, a nuclear protein expressed in all EBV-associated neoplasms is indispensable for the maintenance of the viral episomes in latently infected cells. EBNA1 may induce genetic alterations by upregulating cellular recombinases, production of reactive oxygen species (ROS) and affecting p53 levels and function. All these changes may contribute to tumorigenesis. In this overview we focus, however, on the epigenetic alterations elicited by EBNA1 by drawing a parallel between EBNA1 and the FoxA family of pioneer transcription factors. Both EBNA1 and FoxA induce local DNA demethylation, nucleosome destabilization and bind to mitotic chromosomes. Local DNA demethylation and nucleosome rearrangement mark active promoters and enhancers. In addition, EBNA1 and FoxA, when associated with mitotic chromatin may "bookmark" active genes and ensure their reactivation in postmitotic cells (epigenetic memory). We speculate that DNA looping induced by EBNA1-EBNA1 interactions may reorganize the cellular genome. Such chromatin loops, sustained in mitotic chromatin similarly to the long-distance interactions mediated by the insulator protein CTCF, may also mediate the epigenetic inheritance of gene expression patterns. We suggest that EBNA1 has the potential to induce patho-epigenetic alterations contributing to tumorigenesis.
    12/2012; 1(1):37-51. DOI:10.3390/pathogens1010037
  • [Show abstract] [Hide abstract]
    ABSTRACT: This study was designed to evaluate expression and prognostic significance of runt-related transcription factor (RUNX)-2 in human nonsmall cell lung cancer (NSCLC). RUNX2 expression was examined at mRNA and protein levels by real-time quantitative reverse transcription polymerase chain reaction (qRT-PCR) and Western blot in NSCLC tissues and adjacent normal tissues. In addition, RUNX2 expression was analyzed by immunohistochemistry in 121 clinicopathologically characterized NSCLC cases. The relationship between the expression of RUNX2 and clinicopathological characteristics and prognosis was statistically analyzed. Both qRT-PCR and Western blot demonstrated that RUNX2 mRNA and protein levels were significantly higher in NSCLC tissues compared to the adjacent normal tissues from the same individual. Immunohistochemistry analysis showed that RUNX2 expression was significantly correlated with tumor size, tumor stage, and lymph node metastasis. Higher RUNX2 expression was associated with shorter postoperative survival time of NSCLC patients by Kaplan-Meier method and was found to be an independent risk factor that influences the postoperative survival time of NSCLC patients by Cox regression analysis. In conclusion, these data showed that RUNX2 may play an important role in NSCLC tumorigenesis, and RUNX2 might serve as a novel prognostic marker in NSCLC.
    Tumor Biology 03/2013; 34. DOI:10.1007/s13277-013-0720-4 · 3.61 Impact Factor
Show more